Fig. 3From: Bezafibrate for the treatment of dyslipidemia in patients with coronary artery disease: 20-year mortality follow-up of the BIP randomized control trialIndependent effect of the adjusted risk reduction associated with bezafibrate vs. placebo treatment by pre-specified triglyceride group interaction*. P value for interaction of TG group by treatment allocation = 0.11. *Model further adjusted for age, gender, HDL-C, diabetes, past MI, BMI and glucose levelsBack to article page